Navigation Links
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
Date:6/11/2008

X experienced improvements in disease activity as measured by DAS28. Seventy-six percent of patients in the combined golimumab group were classified as DAS28 (CRP) responders, and 38 percent achieved DAS 28 remission, compared with 61 percent and 28 percent of patients receiving placebo and MTX, respectively (p<0.001 for responders and p=0.031 for remission).

"We are encouraged by the findings of both of these Phase 3 studies," said Robert J. Spiegel, M.D., chief medical officer, Schering-Plough Research Institute. "Golimumab holds great promise as an anti-TNF therapy for patients who may benefit from monthly subcutaneous injections for RA and related rheumatic diseases."

In March 2008, Centocor Inc. and Schering-Plough Corporation (NYSE: SGP) announced that a Marketing Authorization Application (MAA) had been submitted to the European Medicines Agency requesting the approval of golimumab as a monthly subcutaneous treatment for adults with RA, psoriatic arthritis and ankylosing spondylitis. The initial submission and Phase 3 development programs are unprecedented among anti-TNF-alpha therapies, as they mark the first time that an MAA has been proposed for review inclusive of three unique disease states. Golimumab, Centocor's and Schering-Plough's next-generation human anti-TNF-alpha monoclonal antibody, is being studied as an every four-week subcutaneous injection and an intravenous (IV) infusion therapy.

About the GO-FORWARD Trial

GO-FORWARD, a Phase 3, multi-center clinical trial included 444 patients with active RA. Adult patients with more than four tender and swollen joints, despite MTX therapy, were randomly assigned to receive golimumab (50 or 100 mg) plus MTX, golimumab 100 mg plus placebo or placebo plus MTX at weeks 0, 4, 8, 12, 16 and 20. Data were assessed at weeks 14 and 24. The co-primary endpoints were percentage of patients achieving ACR 20 response at week 14 and improvement from baseline in HAQ at week 24.

Golimum
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 3, 2014 British Journal ... BPH to discuss "male orgasmic dysfunction" with their doctor ... treat prostate symptoms while preserving sexual function   ... publication of a paper in the British Journal of ... prostate to discuss with their doctors the likely impact ...
(Date:10/31/2014)... BARCELONA , October 31, 2014 ... two Australian patents of B. Braun Melsungen AG (B. Braun) ... safety IV catheters manufactured by Poly Medicure Ltd ... Australia proceeding number VID 463 of 2013 ... In the detailed judgment, Multigate was found to have infringed ...
(Date:10/31/2014)... 30, 2014 Migranade, Inc. announced today the ... to the 36 million U.S. migraine sufferers November, 2014. ... targets the actual cause of migraines and not just ... not the source Migranade is assured to be a ... Relief is available at http://www.migranade.com and will ...
Breaking Medicine Technology:Sexual Dysfunction No Longer Inevitable When Treating Enlarged Prostate 2B. Braun Wins Patent Disputes Against Poly Medicure Ltd's Australian Distributor Multigate Medical Devices Pty. Ltd. and Spanish Distributor Dextromédica S. L. 2Game Changing Migraine Medication To Be Available November 2014 2
... Jan. 19, 2012 /PRNewswire/ --  Terumo Cardiovascular Systems announced ... with LAAx, Inc. to distribute the TigerPaw® System II, ... The TigerPaw System II is indicated ... visualization, in conjunction with other open cardiac procedures.  It ...
... SAN DIEGO, Jan. 19, 2012  Neurocrine Biosciences, Inc. (Nasdaq: ... an underwritten public offering of 9,500,000 shares of its ... $8.10 per share. The gross proceeds to Neurocrine from ... other offering expenses payable by Neurocrine, are expected to ...
Cached Medicine Technology:Terumo Cardiovascular Systems Becomes Exclusive U.S. Distributor for TigerPaw® System II, Left Atrial Appendage Closure Device 2Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock 2Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock 3
(Date:10/31/2014)... Missouri (PRWEB) October 31, 2014 With ... school, one Midwest optometrist feels they may overlook one ... to affect areas like concentration, school performance and even ... be too brief to identify progressive vision problems, and ... Joseph, Mo., announces a new initiative: The Awesome Eyes ...
(Date:10/31/2014)... News) -- Sleep apnea may make it hard for you ... car or left your house keys, a small study suggests. ... that this ability -- called spatial memory -- was impaired ... when other stages of sleep weren,t affected. REM sleep is ... "We,ve shown for the first time that sleep apnea, ...
(Date:10/31/2014)... that either they or a family member have experienced ... issue of The Gerontological Society of America,s Public ... goes on to show that Americans strongly support holding ... health care wishes. , This PP&AR , titled ... 12 articles that present new ways of understanding the ...
(Date:10/31/2014)... North Shore Eye Care today announced ... Island and the addition of leading ophthalmologist, William S. ... North Shore Eye Care Medical Director, Jeffrey Martin, MD. ... the Department of Ophthalmology of Winthrop-University Hospital and has ... for more than 30 years. He has been named ...
(Date:10/31/2014)... 31, 2014 FindSurrogateMother.com conveys ... gifts of life — building a family through surrogacy. ... mothers and donors with hopeful intended parents in turn ... , It’s a collective aptitude of surrogate mothers, intended ... and fertility clinics that help provide these connections — ...
Breaking Medicine News(10 mins):Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 3Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Advance directives can benefit patients, families, and health care system 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3
... of thyroid cancer is increasing. In this longitudinal study over ... used the Ontario Cancer Registry to identify 7422 cases of ... the jump in the incidence rate of this type of ... annual increase of 13% per year. , In their ...
... Holiday Parties Merry and Safe for Everyone, CHICAGO, ... with the holidays it,s sometimes easy to forget that ... It can be a time when widespread,availability of alcohol ... younger children may view these parties as,opportunities to sneak ...
... GPRO ) announced today that Jorgine Ellerbrock ... "We are pleased to add Jorgine,s extensive ... already strong senior management team," said,Carl Hull, Gen-Probe,s ... Ellerbrock, 46, joins the Company from Invitrogen Corporation,where ...
... needs are vastly different than men,s way beyond their reproductive ... of cardiovascular disease and are more likely to suffer from ... the differences. , Yet, there,s a cavernous void ... have been done on men and the findings applied to ...
... NEW YORK (Nov. 19, 2007) -- Dr. Bruce McCandliss, ... and associate professor of psychology in psychiatry at Weill ... President of the United States in the form of ... (PECASE). The award is the highest honor bestowed by ...
... appears in the current issue of SCAN (Social Cognitive ... School of Medicine discuss how men and women differ ... , We found that different parts of the brain ... and women when they are faced with performance-related stress, ...
Cached Medicine News:Health News:Holidays Can Present Drinking Opportunities for Teens 2Health News:Holidays Can Present Drinking Opportunities for Teens 3Health News:Jorgine Ellerbrock Joins Gen-Probe as Senior Vice President, Operations 2Health News:Women aren't men 2Health News:Women aren't men 3Health News:White House awards Weill Cornell's Bruce McCandliss highest honor for early career scientists 2Health News:Penn researchers use brain imaging to demonstrate how men and women cope differently under stress 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: